Clinical Trial Update: RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART) [Phase 1]

View source ↗

Summary

A Phase 1 trial of RHIV for HIV infections refractory or intolerant to HAART has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• RHIV

Snippet

Sponsor: Atlantic Health System | Conditions: HIV Infections | Phase 1 | Status: WITHDRAWN